Allena Pharmaceuticals, Inc.
ALNA evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Lead Asset:
- alln-346 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ALNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
alln-346 (Preclinical)
Next Catalyst
—
Tracking 2 pipeline candidates for Allena Pharmaceuticals, Inc..
Run Allena Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Allena Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Allena Pharmaceuticals, Inc.'s lead drug candidate?
Allena Pharmaceuticals, Inc.'s most advanced tracked candidate is alln-346 (Preclinical) for hyperuricemia and gout in the setting of advanced CKD.
Who is the CEO of Allena Pharmaceuticals, Inc.?
Louis Brenner, M.D. is the chief executive officer of Allena Pharmaceuticals, Inc. (ALNA).
What therapeutic areas does Allena Pharmaceuticals, Inc. focus on?
Allena Pharmaceuticals, Inc. develops therapies across Metabolic, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.